What is it about?
The emergence of several, novel and pathogenic viral infections have posed a great threat to humanity and could wipe us out of existence if there are no counter measures. Among the increasing number of pathogenic viruses in this past decade, the advent of the recent imperial SARS-CoV-2 coronavirus type cannot be underestimated as it is not just a malady endemic to a nation, but have also triggered an emergency of public health across the globe. In spite the menaces imposed by this viral malady on humanity the availability of licenced vaccines or other curatives to curtail the infection is still lacking. In the lack of potent therapeutic measures the disease will gradually spread and eventually reach a peak that will be difficult to curtail. Realizing, and anticipating the urgency for potent curative measures against COVID-19, Our study attempt to discuss the promising potentialities of SARS-CoV-2 recombinant spike protein-based vaccine as candidate line of defence, and the possibility for development against COVID-19, based on recent research advances on SARS-CoV-2 and the knowledge from researches on SARS-CoV and MERS-CoV.
Featured Image
Photo by Adam Nieścioruk on Unsplash
Why is it important?
SARS-CoV-2 has infrequently cross the species barrier, and is gradually reaching a peak in human population with no arsenals to prevent from its infection. Hence, the search for candidate vaccines and antiviral drugs has acquired considerable interest. Upon realizing the need to curtail this viral malady, we have suggested more consideration into SARS-CoV-2 recombinant Spike protein-based vaccine as an immunotherapeutic target to combat COVID-19. To present a premium for more trials of this vaccine type, we have discussed extensively the potentialities of this vaccines to cure COVID-19 based on garnered knowledge and successful evidences of the vaccine from researches on consanguineal coronaviruses (SARS-CoV, and MERS-CoV), and current trends in vaccine development against this infection.
Perspectives
Writing this article was a great pleasure as it has co-authors with whom I have had long standing collaborations. This article also lead to rare disease groups contacting me and ultimately to a greater involvement in rare disease research.
Prosper Chukwuemeka
Federal University of Technology Akure
Read the Original
This page is a summary of: SARS-CoV-2 Recombinant Spike Protein-based Vaccine: A Promising Candidate against the Recent Imperial Coronavirus Disease (COVID-19), International Journal of Pathogen Research, June 2020, Sciencedomain International,
DOI: 10.9734/ijpr/2020/v4i330115.
You can read the full text:
Contributors
The following have contributed to this page
